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mias. Health-care utilization and cost data for each of the
two patient categories were averaged and annualized.
Costs were converted from local currencies to Euros.
RESULTS: The mean annual health-care costs in patients
with bradycardia alone was 7,787 EUR (95%CI 6,176 to
10,040 EUR) in the US, 3,860 EUR in Germany, and
3,765 EUR in the UK compared to 22,043 EUR (95%CI:
15,060 to 30,759 EUR) in the US, 14,720 EUR in Ger-
many, and 10,407 EUR in the UK for patients with
bradycardia and atrial tachycardias. Atrial tachycardia
results in an additional two- to three-fold increase in
costs per year. The main cost driver in the US and Ger-
many was hospitalizations whereas the main cost driver
in the UK was the cost of procedures.
CONCLUSION: Atrial tachyarrhythmias impose a large
incremental burden on health-care utilization and costs in
bradycardia patients.
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OBJECTIVE: The purpose of this study was to examine
the effect of amlodipine treatment on cardiovascular dis-
ease (CVD) related hospital admissions and the corre-
sponding costs in patients with coronary artery disease
(CAD) in Spain.
METHODS: This analysis used data from Prospective
Randomized Evaluation of the Vascular Effects of Nor-
vasc Trial (PREVENT), a double-blind, randomized, pla-
cebo-controlled, multi-center clinical trial. A decision-
tree model was used to analyze the expected incremental
cost of amlodipine treatment relative to placebo. A sensi-
tivity analysis was conducted to examine the robustness
of the study outcome. The hospital costs were estimated
using the DRG’s from the Medicare adjusted to the me-
dian of a local hospital stay cost (Catalonian area).
RESULTS: Amlodipine significantly reduced the number
of CVD-related hospital admissions and procedures in pa-
tients with CAD relative to placebo. The expected CVD-
related hospital cost per patient in the placebo group ex-
ceeded costs for patients in the amlodipine group. The ex-
pected savings of CVD-related hospitalizations ranged
from 0 to 331 Euros per patient over the trial period in
1997 Spanish pesetas when the cost to charge ratio was
changed from 0.66 to 1.2. The total expected costs for the
amlodipine group were 1,723.5 Euros (533 for no CVD
hospitalization and 1190 for CVD hospitalization) while
the total expected costs for the placebo group were 1929
Euros (119 for No CVD hospitalization and 1810 for
CVD hospitalization). At the breakeven point (the cost to
charge ratio  0.66), the amlodipine treatment still offset
the drug cost of amlodipine.
CONCLUSIONS: Use of amlodipine can reduce CVD-
related hospital admissions and associated costs in pa-
tients with coronary artery disease. Amlodipine is a cost-
saving agent in the treatment of patients with coronary
artery disease.
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OBJECTIVES: To install a world-wide-web (WWW, inter-
net) -based registry for the observation of treatment patterns
for unstable Angina Pectoris (uAP) and to estimate the eco-
nomic burden of uAP in Germany from the perspective of
the statutory health insurance (Gesetzliche Krankenver-
sicherung) and of hospitals as service providers.
METHODS: Prospective, bottom-up, cross-sectional cost-
of-illness (COI) study. Three hundred sixteen patients con-
secutively included between November 2000 and May
2001 were documented via an Internet-based registry us-
ing standardized documentation forms. Inclusion and ex-
clusion criteria were pre-defined. Fifteen centers of differ-
ent healthcare levels (10 university hospitals, 1 specialized
hospital, 4 general hospitals) participated. Direct costs (for
diagnostic, medical treatment, surgery, drug therapy) and
indirect costs (due to lost productivity) associated with in-
patient treatment due to uAP were considered.
RESULTS: Mean age of patients was around 65 years for
females (34%) and 69 years for males (66%). In about
99% of cases, uAP was diagnosed at hospital admission:
47% were hospitalized as emergency cases; 26% were re-
ferred from other hospitals; 26% from office-based phy-
sicians. Mean hospital stay lasts 8.3 days per patient, 6.8
days of them spent in intensive care. Angiography or an-
gioplasty were performed on 78% of patients. About 4%
of patients underwent heart surgery, most of them for tri-
ple coronary bypass. 30% of patients received one of the
new platelet aggregation inhibitors (Abciximab, Eptifi-
batide, Tirofiban) during hospitalization.
CONCLUSIONS: Because the registry is still ongoing, cost
data are under evaluation, but will be finalized for poster
presentation. Treatment with platelet aggregation inhibi-
tors is still not very common, despite being recommended
by German therapy guidelines for uAP treatment.
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OBJECTIVE: With a prevalence up to 40% in the adult
population, chronic venous insufficiency (CVI) is one of
